Recent Additions in the Treatment of Depressive Disorders
New pharmacologic agents have become available for treating depressive disorders and their placement in therapy has yet to be fully elicited. This information is intended to help the pharmacist in determining where and how these new agents can be most effective.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Summarize the safety and efficacy of the recently approved agents for major depressive disorder, treatment refractory depression, and post-partum depression.
- Identify the appropriate patients who will benefit from these new therapies.
- Recognize the expected impact of these newly approved antidepressants in the standard course of treatment for major depressive disorder, treatment refractory depression, and post-partum depression.
Presenter
Michael Angelini, BA, BS, MA, PharmD, BCPP, RPh, is a Professor of Pharmacy Practice at MCPHS in Boston, Massachusetts and a Psychiatric Clinical Pharmacist at Saint Luke’s Hospital in New Bedford, MA. He is also a Psychopharmacology Consultant for Commonwealth Pharmacy Services at the University of Massachusetts Medical School. Additionally, he has been a clinical consultant to primary care, community health centers and group homes throughout New England. He has served on faculty positions in the Addiction Fellowship Program at Boston University School of Medicine, the Massachusetts School of Professional Psychology, and Harvard Medical School. Dr. Angelini earned his Master’s degree in Clinical Psychology at Boston University and his Doctor of Pharmacy degree at MCPH . Board-certified in Psychiatric Pharmacy, Dr. Angelini has published chapters in therapeutics textbooks, study guides and articles in peer-reviewed journals. Dr. Angelini is a member of the American Association of Colleges of Pharmacy and the Massachusetts Pharmacists Association.
Registration Fee: Free for MCPHS alumni, faculty and staff. For all others the fee is $12.00
Release Date: December 4, 2020
Expiration Date: December 7, 2022
Contact Hours: 1.0 (0.1 CEU)
ACPE UAN: 0026-0000-20-207-H01-P | Knowledge
ACPE Topic Designator: Disease State Management/Drug Therapy
Massachusetts College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Massachusetts College of Pharmacy and Health Sciences designates this activity for a total of 1 contact hour (0.1 CEUs).
In order to receive credit, the participant must view the entire presentation and complete the pre and post-tests, and evaluation form. Upon completion, participant credit will be reported to CPE Monitor. Transcripts may be printed from CPE Monitor.
Massachusetts College of Pharmacy and Health Sciences adheres to the ACPE Standards for Integrity and Independence in Continuing Education. It is the policy of MCPHS that the speakers and planning committee members disclose all financial relationships with ineligible companies within the last 24 months, and that relevant conflicts of interest are mitigated. Speakers will disclose any off-label/unapproved use of drugs or devices during their presentation.
Dimple Gandhi, PharmD, RPh, is an MCPHS post-doctoral Biopharmaceutical Fellow at Takeda Pharmaceuticals, an ineligible company. The content of this presentation does not relate to the product lines or solutions produced or offered by Takeda Pharmaceuticals.
Content Reviewer, Paul Belliveau, PharmD, holds no financial relationships with ineligible companies.
Massachusetts College of Pharmacy and Health Sciences Continuing Education staff members hold no financial relationships with ineligible companies, related to the content of this presentation.
No funding from industry provided for this event. No exhibitors will be present.